Cancer risks from diabetes therapies: evaluating the evidence.

@article{Li2014CancerRF,
  title={Cancer risks from diabetes therapies: evaluating the evidence.},
  author={Chen Li and Deling Kong},
  journal={Pharmacology & therapeutics},
  year={2014},
  volume={144 1},
  pages={
          71-81
        }
}
Epidemiological studies have identified positive associations between diabetes, obesity and cancer. Insulin, metformin and thiazolidinediones (TDZs) are among the major diabetes therapies that improve glycaemic control by acting via molecular targets including the insulin receptor and insulin-like growth factor pathways, adenosine monophosphate-activated kinase and peroxisome proliferator-activated receptor γ. It is well-established that clinical application of insulin and TDZs is associated… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 100 REFERENCES

Thiazolidinediones and PPARγ agonists: time for a reassessment

  • Trends in Endocrinology & Metabolism
  • 2012
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

The IGF-1 receptor in cancer biology.

  • International journal of cancer
  • 2003
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Cancer risks from diabetes

C. Li, D. Kong
  • 2014